[Pratical aspects of anti-Ige therapy in severe allergic asthma].
Omalizumab is an anti-IgE monoclonal antibody, available on the swiss market since november 2006, with the indication as add on therapy for the treatment of poorly controlled severe persistent allergic asthma. These severe asthmatics consume a great share of the resources dedicated to asthma. Many randomised controlled studies have demonstrated the efficacy of omalizumab in reducing exacerbation and requirement of inhaled corticosteroids and in improving quality of life. Omalizumab is reimbursed in Switzerland for adults and children over 12 years of age, with objective markers of atopy and total IgE ranging between 30 et 700 UI/ml. Only allergists and respiratory physician can prescribe this drug in Switzerland. This reyiew focuses on the rationale, indications and practical use of anti-IgE therapy.
Taramarcaz
P
P
Service d'immunologie et allergologie, HUG, 1211 Geneve 14. Philip.Taramarcaz@hcuge.ch
Hauser
C
C
Rochat
T
T
D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D000069444:Omalizumab; D012720:Severity of Illness Index
D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab; D007073:Immunoglobulin E